Article Sidebar

pdf
Date Published: 16/09/2025
Abstract Views: 168
Views pdf: 65
DOI: https://doi.org/10.51298/vmj.v553i2.15326
Issue
Vol. 553 No. 2 (2025)
Section
Các bài báo
How to Cite
Trần Tiến, Đạt, Nguyễn Thuận, L., & Từ Quang, A. (2025). PD-L1 EXPRESSION CHARACTERISTICS IN PATIENTS WITH LUNG ADENOCARCINOMA AT BACH MAI HOSPITAL. Vietnam Medical Journal, 553(2). https://doi.org/10.51298/vmj.v553i2.15326

PD-L1 EXPRESSION CHARACTERISTICS IN PATIENTS WITH LUNG ADENOCARCINOMA AT BACH MAI HOSPITAL

Đạt Trần Tiến, Lợi Nguyễn Thuận, Anh Từ Quang

Main Article Content

Abstract

Adenocarcinoma is the most common histological subtype of lung cancer in Vietnam and is often associated with poor prognosis. Immune checkpoint inhibitor therapy targeting PD-1/PD-L1 has shown promise in improving treatment outcomes and prolonging survival. Objective: To investigate the expression of PD-L1 and its association with selected clinical and paraclinical factors in patients with lung adenocarcinoma at Bach Mai Hospital. Subjects and Methods: A cross-sectional descriptive study was conducted on 182 patients at Bach Mai Hospital. PD-L1 expression was evaluated using immunohistochemistry with the PD-L1 22C3 pharmDx antibody. Results: The PD-L1 positive rate was 51.6%, including 28.5% with low expression (TPS 1–49%) and 23.1% with high expression (TPS ≥50%). Negative expression (TPS <1%) was observed in 48.4% of cases. PD-L1 expression was significantly higher in male patients (58.1%) compared to females (32.8%), and in patients with a history of smoking (58.7%) versus non-smokers (41%), with p-values of 0.011 and 0.020, respectively. No significant associations were found between PD-L1 expression and other factors such as age, TNM stage, biopsy site, EGFR mutation status, or maxSUV index. Conclusion: High-level PD-L1 expression in patients with lung adenocarcinoma is associated with male gender and a history of smoking. These findings contribute to guiding the selection of appropriate patients for immunotherapy, supporting the personalization of lung cancer treatment in Vietnam.

Article Details

Keywords

Lung adenocarcinoma, PD-L1, immunotherapy

References

1. Phạm Minh Lanh (2019). Nhận xét đặc điểm bộc lộ PD-L1 ở bệnh nhân ung thư phổi không tế bào nhỏ tại Bệnh viện Bạch Mai năm 2018 – 2019. Khóa luận tốt nghiệp ngành Y Khoa, Trường Đại học Y Dược, Đại học Quốc Gia Hà Nội.
2. Le H, Hiep L, Hong D (2022). Clinical and subclinical of non-small cell lung cancer stage IIIB-IVB patients with positive PD-L1. Tạp chí Y học lâm sàng, 129, 178–185.
3. Rashed H.E., Abdelrahman A.E., Abdelgawad M., et al. (2017). Prognostic significance of programmed cell death ligand 1 (PD-L1), CD8+ tumor-infiltrating lymphocytes and p53 in non-small cell lung cancer: an immunohistochemical study. Turk Patoloji Dergisi, 1(1), 211–222.
4. Rodriguez-Lara V., Soca-Chafre G., Avila-Costa M.R., et al. (2023). Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications. Frontiers in Oncology, 13, 1210297.
5. Rizvi N.A., Hellmann M.D., Snyder A., et al. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science, 348(6230), 124–128.
6. Cha Y.J., Kim H.R., Lee C.Y., Cho B.C., Shim H.S. (2016). Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer, 97, 73–80.
7. Munari E., Rossi G., Zamboni G., et al. (2016). PD-L1 expression heterogeneity in non–small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. Journal of Thoracic Oncology, 13(8), 1113–1120.
8. Schoenfeld A.J., Rizvi H., Bandlamudi C., et al. (2020). Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of Oncology, 31(5), 599–608.